Lack of effect of celecoxib on prostaglandin E2 concentrations in nipple aspirate fluid from women at increased risk of breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 11, 2004, Pages 1745-1750

  Sauter, Edward R ^a   Schlatter, Lisa ^a   Hewett, John ^a   Koivunen, Debra ^a   Flynn, John T ^b  

^a University of Missouri   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; PROSTAGLANDIN E2;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST DISCHARGE; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMOLUMINESCENCE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; FEMALE; HUMANS; MIDDLE AGED; NIPPLES; PYRAZOLES; RISK FACTORS; SULFONAMIDES;

EID: 8344222953     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Fisher B. Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. CA Cancer J Clin 1999;49:159-77.
2. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998;90:1609-20.
3. Meagher EA. Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications. Drug Saf 2003;26:913-24.
4. Whittle BJ. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 2003;17:301-13.
5. 2) levels in human breast cancer are associated with poor long-term survival. Proc AACR 2000;41:3660A.
6. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
7. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-60.
8. Alshafie G, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in a rat mammary rumor model. Proc AACR 2000;41:3144A.
9. Lanza-Jacoby S, Miller S, Flynn J, et al. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev 2003;12:1486-91.
10. Chan AT. Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention. Cancer Causes Control 2003;14:413-8.
11. Center for Drug Evaluation and Research, Food and Drug Administration. Draft label, celebrex (celecoxib); 1999. Available from: http://www.fda.gov/ cder/drug/.
12. Sauter ER, Ross E, Daly M, et al. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer 1997;76:494-501.
13. Renzi PM, Flynn JT. Endotoxin enhances arachidonic acid metabolism by cultured rabbit microvascular endothelial cells. Am J Physiol 1992;263:H1213-21.
14. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
15. Phillips RK, Wallace MH, Lynch PM, et al. A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857-60.
16. 2 in pregnant women undergoing labor induction with endocervical gel application. Rev Esp Med Nucl 1999;18:268-71.
17. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101-3.
18. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 2001;21:3425-32.
19. Howe LR, Subbaramaiah K, Patel J, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002;62:5405-7.
20. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-45.
21. Watanabe O, Shimizu T, Imamura H, et al. Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res 2003;23:3215-21.
22. Sucic M, Boban D, Markovic-Glamocak M, et al. Expression of cydooxygenase-2 in fine-needle aspirates from breast carcinoma and benign breast diseases. Breast 2003;12:51-7.
23. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004;90:423-9.
24. Denkert C, Winzer KJ, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer 2004;4:428-33.